Scientific Considerations for the Review and Approval of First Generic Mometasone Furoate Nasal Suspension Spray in the United States from the Bioequivalence Perspective
- 92 Downloads
In 2016, the US Food and Drug Administration (FDA) approved the first Abbreviated New Drug Application for Mometasone Furoate Nasal Suspension Spray. To establish the bioequivalence of this generic nasal suspension spray with the reference listed drug product (RLD), Nasonex®, a “weight-of-evidence” approach was utilized by the applicant that included formulation and device similarities, equivalent in vitro performance, equivalent systemic exposure, and equivalent local delivery. In addition to these testing for comprehensive evaluation of the drug product, FDA also considered supportive data generated by a novel in vitro method, Morphologically-Directed Raman Spectroscopy (MDRS), to characterize the particle size distribution (PSD) of active pharmaceutical ingredient (API) in the drug product. In this case, MDRS data eliminated the need for a comparative clinical endpoint bioequivalence study. The approval of the first generic Mometasone Furoate Nasal Suspension Spray is precedent-setting and paves a new pathway to establish bioequivalence for generic nasal suspension sprays. This approval also exemplifies FDA’s commitment to advance regulatory science for evaluation of generic drug products.
KEY WORDSbioequivalence weight-of-evidence nasal suspension spray particle size distribution
Compliance with Ethical Standards
This article reflects the views of the author and should not be construed to represent the Food and Drug Administration’s view or policies.
- 2.https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=320.23. Last assessed 07/08/2018.
- 3.FDA. US. FDA Draft Guidance for Industry. Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action. 2003. https://www.fda.gov/downloads/Drugs/.../Guidances/ucm070111.pdf.
- 5.https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM461141.pdf (Recommended September 2015).
- 6.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12df48a0-fd2e-4e1c-b135-e616a1f31f42 (Updated December 19, 2017).
- 11.Advisory Committee for Pharmaceutical Science, 07/17/2001.Google Scholar
- 12.Shur J, Farias G, Huck-Jones D, O'Grady C, Saluja B, Price R. Characterizing nasal suspensions for regulatory and scientific purposes. Respiratory Drug Delivery 2016. Google Scholar
- 13.Budesonide Inhalation Suspension Drug Label Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c52c5382-1400-44b9-95be-a30e1cf706da. (Updated December 11, 2018).
- 14.https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM319977.pdf (Recommended September 2012).
- 15.https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM520271.pdf (Recommended October 2016).